06th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220040212 | ORAL REHYDRATION COMPOSITION WITH OLIGOSACCHARIDES - The general inventive concepts are directed to compositions and methods for the prevention and treatment of dehydration. Provided herein are nutritional compositions including oral rehydration compositions. Certain embodiments of the nutritional compositions have an acidic pH, and comprise a digestible carbohydrate, sodium, citrate, and an oligosaccharide selected from a fucosylated oligosaccharide and an N-acetylated oligosaccharide. | 2022-02-10 |
20220040213 | METHODS OF TREATING CANCER USING PLATANOSIDE AND ISOMERS THEREOF - This invention relates to methods of treating cancer with platanoside and/or isomers thereof or pharmaceutically acceptable salts thereof, particularly treatment of a pancreatic, liver or brain cancer. This invention further relates to methods of treating cancer with platanoside and/or isomers thereof, produced from | 2022-02-10 |
20220040214 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I): | 2022-02-10 |
20220040215 | MUSCLE TREATMENT COMPOSITION AND METHOD OF MAKING SAME - A topical treatment composition for treating muscle cramps, muscle stiffness, muscle pain or muscle spasms. The treatment composition includes a middle (mid) chain fatty acid (MCFA). A method of making the topical treatment composition is also disclosed herein. | 2022-02-10 |
20220040216 | METHOD FOR SELECTING CELLS, METHOD FOR PRODUCING NUCLEIC ACID, METHOD FOR PRODUCING RECOMBINANT CELLS, METHOD FOR PRODUCING TARGET SUBSTANCE, METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITION, AND REAGENT - To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate | 2022-02-10 |
20220040217 | PHARMACEUTICAL COMPOSITION FOR IMMUNE ACTIVITY OR FOR PREVENTING OR TREATING CANCER - A composition according to an embodiment of the present disclosure includes a blunt-ended hairpin RNA; and porous silica particles carrying the RNA in pores thereof, wherein the porous silica particles have an average pore diameter of 7 to 25 nm, and the inside of the pores is positively charged, thus to sufficiently support the RNA and stably deliver the supported RNA into the body. The composition may improve immune activity and prevent or treat cancer. | 2022-02-10 |
20220040218 | Therapeutic RNA for Advanced Stage Solid Tumor Cancers - This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-1 and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy. | 2022-02-10 |
20220040219 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS - The present invention is directed to a method for treating cystic fibrosis (CF) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 23 of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Also provided are a composition and a kit comprising the splicing modulator, and a method of producing thereof. | 2022-02-10 |
20220040220 | TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS - Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (1fTSLP). | 2022-02-10 |
20220040221 | HYDROGEL TABLET FOR RELIEVING ALCOHOLISM AND PROTECTING THE LIVER AS WELL AS PREPARATION PROCESS AND APPLICATION THEREOF - The present disclosure provides a hydrogel tablet for relieving alcoholism and protecting the liver as well as the preparation process and application thereof. The present disclosure firstly provides a composition with the effects of relieving alcoholism and protecting the liver, which comprises the following components on the basis of weight parts: 20˜40 parts of chitosan, 25˜55 parts of sodium alginate, 3˜20 parts of gelatin, 1˜10 parts of calcium carbonate and 0.05˜0.5 parts of gallic acid. Based on this composition, the present disclosure further provides a hydrogel tablet for relieving alcoholism and protecting the liver. In the present disclosure, chitosan, sodium alginate and calcium carbonate are compounded at an appropriate proportion to form powder particles of chitosan/sodium alginate (shell)-calcium carbonate (core), into which are additionally added gelatin and gallic acid to get a product that is the hydrogel tablet. | 2022-02-10 |
20220040223 | ANTIMICROBIAL GUANIDINIUM MACROMOLECULES WITH BACTERIA TARGETING MOIETIES - Compositions and methods regarding antimicrobial guanidinium macromolecules with one or more targeting moieties for selectively targeting bacteria are provided. According to an embodiment, an antimicrobial macromolecule is provided that comprises a polymer backbone and one or more guanidinium moieties that extend from the polymer backbone. The antimicrobial macromolecule further comprises a targeting moiety that extends from the polymer backbone. The targeting moiety can comprise a substance favored for consumption by bacteria, such as a monosaccharide. | 2022-02-10 |
20220040224 | NITRIC OXIDE TOPICAL APPLICATION APPARATUS AND METHODS - A topical application of nitric oxide may be provided by two separate containers, each containing an active component media to produce nitric oxide when combined. For example, a nitrite component media may be contained in one dispenser and an acidified component media may be contained in another dispenser. Each dispenser may dispense the respective component media as a foam. The resultant foams are combined to initiate the production of nitric oxide and the mixture of foams is applied topically to treat various skin disorders or wounds. | 2022-02-10 |
20220040225 | METHOD OF ADMINISTRATION AND TREATMENT - Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described hemin. | 2022-02-10 |
20220040226 | SYNERGISTIC MEDICINAL COMPOSITIONS FOR TREATING DYSFUNCTIONAL D-SERINE SIGNALING - The invention disclosed herein relates to novel synergistic medicinal compositions for treating dysfunctional D-serine (DSR) signaling. Particularly the invention provides potent synergistic medicinal composition comprising combination of N-acetyl taurinate salt of divalent metal (M | 2022-02-10 |
20220040227 | METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME - A method of treating a Corona Virus, e.g., COVID 19, Influenza and ARDS, is provided. A copper chelator including a tetrathiomolybdate salt is administered with a 5-lipoxygenase enzyme inhibitor, e.g., Diethylcarbamazine or Zileuton. Baicalin, Bufalin, Quercetin, Curcumin, inhibitors of NF-kappaB, the Applied Therapeutics Aldose Reductase inhibitor AT-001, Sulforaphane or Fluvoxamine can be additional drugs. This is an intervention treatment of a Corona Virus, e.g., COVID 19, ideally in the second phase of the disease, in the Pulmonary Phase, preferably prior to the Hyper-Inflammation Phase, as a preventive therapy to reduce the need for a ventilator and increase the survival of hospitalized patients. The two-drug treatment combination aims at preventing ARDS and other organ damage caused by COVID 19 infection by targeting the intravascular disease component. Tetrathiomolybdate in oral and Intravenous forms combined with the other drugs in intravenous or inhaled forms are designed to treat advanced forms of these diseases. | 2022-02-10 |
20220040228 | MATERIALS AND METHODS FOR STOPPING RESPIRATORY VIRUS INFECTIONS - The subject invention pertains to the use of zinc, zinc ionophore, one or more vitamins, folate, selenium, garlic, and/or Echinacea as a treatment of viral infections, and the training needed for subjects to recognize such symptoms to be able to stop respiratory viral infections including colds flu and coronavirus, or to prevent respiratory virus infections, such as SARS-CoV-2 infections. The subject invention further pertains to pharmaceutical compositions, packaged dosage formulations, and kits for stopping respiratory virus infections, or for preventing respiratory virus infections in contact subjects that might have such infections. | 2022-02-10 |
20220040229 | MATERIALS AND METHODS FOR TREATING CANCER - This document provides methods and materials involved in treating cancer. For example, chimeric antigen receptor T cells having reduced levels of GM-CSF are provided. Also provided as methods for making and using chimeric antigen receptor T cells having reduced levels of GM-CSF | 2022-02-10 |
20220040230 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES - The present application relates to pharmaceutical compositions comprising multiple cell types, and methods of using these compositions to treat cancer in a subject. | 2022-02-10 |
20220040231 | COMBINATION THERAPY OF ARMS AND NATURAL KILLER CELLS - Among other things, the present disclosure provides technologies comprising immune cells and antibody-recruiting molecules. In some embodiments, immune cells are memory-like natural killer cells. In some embodiments, provided technologies are particularly useful for treating a condition, disorder or disease like cancer. In some embodiments, provided technologies provide high efficacy. In some embodiments, provided technologies provide less or less severe side effects associated with natural killer cell therapy. | 2022-02-10 |
20220040232 | MATERIALS AND METHODS FOR PRODUCING BIOENGINEERED VIRUS SPECIFIC LYMPHOCYTES - A method for activating or enriching Vβ17 | 2022-02-10 |
20220040233 | PLASMID COMBINATION AND APPLICATION THEREOF IN PREPARING MODIFIED IMMUNE CELLS - Provided in the present disclosure is a method for using a four-plasmid system to prepare modified immune effector cells. The method comprises: forming a lentivirus by using four plasmids within 293T cells, extracting and obtaining the lentivirus, then transfecting immune effector cells by using the lentivirus, and expressing a chimeric antigen receptor. Also provided in the present disclosure is a use of the immune effector cell obtained by using the described method and of a composition containing the immune effector cell. | 2022-02-10 |
20220040234 | CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF - A chimeric antigen receptor, comprising an amino acid sequence shown in SEQ ID NO. 1. A nucleic acid encoding the chimeric antigen receptor, a vector comprising the nucleic acid, an immune effector cell comprising the chimeric antigen receptor, the nucleic acid molecule and/or the vector, a method for preparing the immune effector cell, a composition comprising the immune effector cell, and use of the chimeric antigen receptor. | 2022-02-10 |
20220040235 | IMMUNE CELLS DEFECTIVE FOR SUV39H1 - The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer. | 2022-02-10 |
20220040236 | COMPOSITIONS AND METHODS OF TREATMENT OF VISION LOSS THROUGH GENERATION OF ROD PHOTORECEPTORS FROM MULLER GLIAL CELLS - The present invention provides methods and compositions for inducing differentiation of Müller glial cells into rod photoreceptors through a two-step process of inducing Müller glial cell proliferation by increasing WNT signaling effectors in the Müller glial cell and then directed differentiation into a rod photoreceptor through activation of rod-specific photoreceptor genes. The methods and compositions are useful in a method of treating vision loss or impairment due to photoreceptor loss. The present invention also provides methods for treating vision loss or impairment in a subject comprising (a) administering to the subject a therapeutically effective amount of a Müller glial (MG) cell proliferation agent; and (b) a period of time after the administering of step (a), administering to the subject a therapeutically effective amount of a MG cell differentiation agent. | 2022-02-10 |
20220040237 | OXYGENATED DEMINERALIZED BONE MATRIX FOR USE IN BONE GROWTH - An improved composition for inducing bone growth is provided that is a combination of at least DBM and an oxygen carrier. Injection/implantation of a composition of DBM and an oxygen carrier (e.g. a perfluorocarbon) results in enhancement of bone formation compared to DBM alone. | 2022-02-10 |
20220040238 | COMPOSITION COMPRISING INDUCED EXOSOME FOR HAIR REGENERATION - A method for producing exosomes comprises steps of: providing ultrasound stimulation directly or indirectly to cells; culturing a mixture of the cells and a medium for a predetermined time; and isolating exosomes from the mixture, wherein providing the stimulation directly to the cells comprises applying ultrasound stimulation to the medium containing the cells, and the providing the stimulation indirectly to the cells comprises applying ultrasound stimulation to the medium not containing the cells and then mixing the medium and the cells. This method for producing exosomes makes it possible to obtain exosomes having a hair regeneration effect not only from stem cells and progenitor cells that are difficult to isolate and multiply, but also from somatic cells that may be easily obtained and maintained, in high yield within a short time by ultrasound treatment that is a simple process. | 2022-02-10 |
20220040239 | THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND A STEROID FOR THE TREATMENT OF EVOLVING BPD - Administering a pulmonary surfactant and a corticosteroid is effective for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates. | 2022-02-10 |
20220040240 | COMPOSITION FOR IMPROVING COGNITIVE ABILITY AND PREVENTING OR TREATING DEMENTIA AND ATTENTION DEFICIT HYPERACTIVITY DISORDER, COMPRISING GALLA RHOIS EXTRACT AND FRAXIN AS ACTIVE INGREDIENTS - The present invention relates to a composition for improving cognitive ability, and preventing or treating dementia and a hyperactivity disorder, which includes a | 2022-02-10 |
20220040241 | FEED ADDITIVE COMPOSITION - A feed additive composition comprising a direct fed microbial (DFM), in combination with a xylanase (e.g. endo-1,4-β-d-xylanase) and a β-glucanase (and optionally a further fibre degrading enzyme). | 2022-02-10 |
20220040242 | MODULATION OF THE GUT MICROBIOME TO TREAT MENTAL DISORDERS OR DISEASES OF THE CENTRAL NERVOUS SYSTEM - The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA. | 2022-02-10 |
20220040243 | LACTOBACILLUS PLANTARUM KBL396 STRAIN AND USE THEREOF - The present invention relates to a composition comprising at least one selected from the group consisting of a novel lactic acid bacterium, | 2022-02-10 |
20220040244 | PROBIOTICS FOR COGNITIVE AND MENTAL HEALTH - The invention relates to compositions comprising | 2022-02-10 |
20220040245 | USE OF MICROBIAL COMMUNITIES FOR HUMAN AND ANIMAL HEALTH - The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder. | 2022-02-10 |
20220040246 | PSYCHOACTIVE ALKALOID EXTRACTION AND COMPOSITION WITH CONTROLLED DEPHOSPHORYLATION - This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids. | 2022-02-10 |
20220040247 | USE OF FAT-SOLUBLE EXTRACT OF BRUCEA JAVANICA L. MERR IN PREPARING MEDICINES FOR PROMOTING PERIPHERAL NERVE REGENERATION - A fat-soluble extract of | 2022-02-10 |
20220040248 | Prevention of Neuroinflammation associated Memory Loss Using Nutraceutical Compositions - Disclosed are means, methods, and therapeutic compositions for prevention of memory loss during situations of neuroinflammation. In one embodiment the invention teaches administration of the therapeutic combination of ingredients comprising of pterostilbene, | 2022-02-10 |
20220040249 | LIQUID INVISIBLE MASK WITH BROAD-SPECTRUM BACTERIOSTASIS AND PREPARATION METHOD AND USING METHOD THEREOF - A liquid invisible mask, and a preparation method and a using method thereof are provided by the present disclosure, and the present disclosure relates to the technical field of isolated bacteriostatic protective materials. The liquid invisible mask which is a film covering a surface of a nasal cavity, an oral cavity or a throat mucosa, wherein: the film comprises a garlic extract with garlicin content more than 45%, sesame essential oil and cream; and a mass ratio of the garlic extract, the sesame essential oil and the cream is (70-85):(10-20):(5-10). The present disclosure takes the garlic extract with high content of garlicin as the active component, ensures the basic efficacy of sterilization and toxicity elimination, and is supplemented with sesame essential oil as the film-forming carrier material and cream as the skeleton material. | 2022-02-10 |
20220040250 | STABLE PALM INFLORESCENCE SAP POWDER COMPOSITIONS AND ITS PHARMACOLOGICAL EFFECTS - The present invention provides a coconut sap inflorescence powder compositions to provide symptomatic or prophylactic treatment of human disorder that has enriched vitamins, minerals, fat, carbohydrates and proteins. The invention also provides a process for producing such powders by spray drying or freeze drying. The powdered compositions and dosage forms are useful in the treatment of drug induced nephrotoxicity, alcoholic liver damage, and performance enhancement when administered orally. | 2022-02-10 |
20220040251 | COMPOSITIONS AND METHODS FOR NUTRITIONAL SUPPLEMENTS - Compositions and methods are presented in which a plurality of chemically distinct polyphenols inhibit multiple enzymes in pathways associated with health and healthy ageing. Preferred compositions are derived from colored plant materials that are commonly found in the Mediterranean diet and provide the biochemical basis for the health benefits of the Mediterranean diet. Notably, the enzyme inhibition observed with the combined polyphenols was synergistic with respect to not one but a significant number of enzymes in the pathways associated with health and healthy ageing, thus providing an amplified desirable effect. | 2022-02-10 |
20220040252 | TREATMENT OF PROSTATE CANCER BY ANDROGEN ABLATION AND IL-8 BLOCKADE - A method of treating prostate cancer by administration of an IL-8 blocker in combination with androgen ablation. | 2022-02-10 |
20220040254 | METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS - In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma. | 2022-02-10 |
20220040255 | CHEMOTHERAPEUTIC REMODELING OF THE GUT MICROBIOME - The present invention provides methods for remodeling gut microbiome to a desired state. The invention also provides in vitro screening platform for identifying novel agents that can remodel dysfunctional gut microbiome. | 2022-02-10 |
20220040256 | ARTHROFACTIN FOR THE TREATMENT OF ACNE - The present invention relates to a mixture of arthrofactin or of a composition containing it and to the use thereof for the treatment of acneic skin. | 2022-02-10 |
20220040257 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING ATHEROSCLEROSIS AND RELATED DISEASES - A method for preventing or treating atherosclerosis or atherosclerosis-related diseases in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of sDSS1 protein or a fragment or variant thereof, a nucleic acid encoding the sDSS1 protein or a fragment or variant thereof or a vector containing the nucleic acid, transplanting into the individual with a cell expressing the sDSS1 protein or a fragment or variant thereof, or tissues or organs containing the sDSS1 protein or a fragment or variant thereof or the nucleic acid, and/or infusing into the individual serum or interstitial fluid containing the sDSS1 protein or a fragment or variant thereof or the nucleic acid. | 2022-02-10 |
20220040258 | GASTRO-RESISTANT MICROENCAPSULATES, AND USES THEREOF TO STIMULATE IN-VIVO ILEAL GLP-1 RELEASE IN A MAMMAL - A cold-gelated mono-nuclear microencapsulate comprises a unitary liquid core encapsulated within a gastro-resistant, ileal-sensitive, polymerized denatured protein membrane shell, wherein the liquid core comprises a GLP-1 release stimulating agent in a substantially solubilised form. The GLP-1 release stimulating agent is a native protein selected from native dairy protein, native vegetable protein or native egg protein. | 2022-02-10 |
20220040259 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. | 2022-02-10 |
20220040260 | ANTIEPILEPTIC TOXIN MARTENTOXIN AND USE THEREOF - The present invention provides uses for the anti-epileptic toxin Martentoxin and derivatives thereof. Specifically, the present invention provides the use of Martentoxin (or MarTX toxin) or an active fragment thereof or a pharmaceutically acceptable salt thereof in preparing a preparation or composition for treating and/or preventing epilepsy. | 2022-02-10 |
20220040261 | COMPOSITION FOR TREATING HAIR LOSS OR PROMOTING HAIR GROWTH - The present invention relates to a composition for treating hair loss or promoting hair growth which contains a silk protein, and plasma or serum components. According to the present invention, due to the synergistic effect of a silk protein and plasma or serum components, the effect of promoting hair growth and the effect of treating hair loss can be expected to be more efficient. | 2022-02-10 |
20220040262 | THERAPEUTIC USE OF TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF FOR LIVER DISEASE - The present invention relates to therapeutic uses of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, and long-acting conjugates thereof for liver disease. | 2022-02-10 |
20220040263 | COMPANION DIAGNOSTIC FOR COMBINATION LENALIDOMIDE AND ERYTHROPOIETIN TREATMENT - Disclosed herein is a companion diagnostic to predict efficacy of combination lenalidomide and erythropoietin treatment in patients with a erythropoietin (Epo)-refractory, Lower Risk (LR) Non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS). The method involves assaying erythroid precursors from a biological sample from the subject for a CD45 isoform profile, and treating the subject with a combination of lenalidomide and erythropoietin if the erythroid precursors have a predominance of large CD45RA and CD45RB isoforms compared to small CD45RO isoform. | 2022-02-10 |
20220040264 | IL-15/IL-15RA HETERODIMERIC FC FUSION PROTEINS AND USES THEREOF - The present invention is directed to novel IL-15/IL-15Rα heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15Rα heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15Rα heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody. | 2022-02-10 |
20220040265 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR INHIBITING VIRAL INFECTION AND SPREAD - Use of an interferon (INF), whether Type I (e.g. interferon-alpha, interferon-beta, etc.), Type II (e.g. interferon-gamma) and/or Type III (e.g. interferon-lamda), for inhibiting and/or preventing coronavirus infection in people, including but not limited to those people at risk of exposure to COVID 19 and/or variants thereof. | 2022-02-10 |
20220040266 | GROWTH HORMONE ANTAGONIST AND ANTI-CANCER COMPOSITION COMBINATION THERAPY - A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising a modified human growth hormone receptor antagonist; and an anti-cancer composition. A method for treating cancer using human growth hormone antagonists, comprising pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition. | 2022-02-10 |
20220040267 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES - Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed. | 2022-02-10 |
20220040268 | METHOD FOR IMPROVING SKIN CONDITION WITH BIOACTIVE COMPOUND - A method for improving a skin condition of a subject in need thereof includes administering to the subject a composition including a bioactive compound. The bioactive compound is a peptide, and includes at least one amino acid sequence as set forth in SEQ ID NO: 1 to SEQ ID NO: 11. Each of the amino acid sequence is a peptide of fish skin. | 2022-02-10 |
20220040269 | PET FOOD FORMULATION WITH CANNABINOIDS - A food supplement is disclosed that comprises an extracellular matrix composition of hydrolyzed collagen, hyaluronic acid and glucosamine, ascorbic acid and, optionally, a cannabinoid composition. The food supplement can be given to pet animals for the relief of or prophylaxis of degenerative joint diseases, such as arthritis. | 2022-02-10 |
20220040270 | AGENT AND COMPOSITION FOR IMPROVING INTRAUTERINE BACTERIAL FLORA, AND METHOD FOR DETERMINING WHETHER INTRAUTERINE BACTERIAL FLORA HAS BEEN IMPROVED OR NORMALIZED - The purpose of the present invention is to provide an agent for improving intrauterine bacterial flora, and a method for determining whether intrauterine bacterial flora has been improved or normalized. An aspect of the present invention is an agent for improving intrauterine bacterial flora that contains lactoferrin or a salt thereof as an active ingredient. Additionally provided are: an agent or composition for improving intrauterine flora or treating or preventing diseases caused by the imbalance of intrauterine bacterial flora, the agent or composition containing lactoferrin or a salt thereof; a method for treating or preventing diseases caused by imbalance of intrauterine bacterial flora, the method comprising administrating the agent or composition; and a method for determining whether intrauterine bacterial flora has been improved or normalized. | 2022-02-10 |
20220040271 | ANIMAL FEED COMPOSITIONS AND USES THEREOF - The present invention relates to animal feed compositions comprising polypeptides having muramidase activity and carotenoids and uses thereof. | 2022-02-10 |
20220040272 | METHOD OF TREATING A MAMMAL, INCLUDING HUMAN, AGAINST CANCER USING METHIONINE AND ASPARAGINE DEPLETION - The invention is related to a new method for treating liquid and solid cancers, in a mammal, including human, wherein methioninase is administered before asparaginase. The invention also encompasses the use of a dietary methionine deprivation, possibly combined with methioninase administration, in advance of asparaginase treatment. Methioninase and asparaginase may be used in particular under free form, pegylated form or encapsulated into erythrocytes. | 2022-02-10 |
20220040273 | Vaccine Used For Preventing Toxoplasma Gondii Infection And Preparation Method Therefor - Provided is a protein having | 2022-02-10 |
20220040274 | METHOD FOR BLOCKING ANTIBODY ADMINISTRATION IN TRANSPLANTATION - A method can include determining a donor-specific human leukocyte antigen of a tissue transplant recipient; determining a ratio of the tissue transplant recipient for a level of an immunoglobulin G subclass 4 antibody (G4) for the antigen with respect to a level of another immunoglobulin G subclass antibody for the antigen; and, based on the ratio, deciding to administer an amount of the G4 to the tissue transplant recipient. | 2022-02-10 |
20220040275 | BREAST AND OVARIAN CANCER VACCINES - The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof. | 2022-02-10 |
20220040276 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS - The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). | 2022-02-10 |
20220040277 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-02-10 |
20220040278 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-02-10 |
20220040279 | NEOANTIGEN COMPOSITIONS; AND METHODS OF PREPARATION AND USE THEREOF - The disclosure provides methods of producing neoantigens, comprising bringing a tumor cell culture in contact with an antisense oligonucleotide; and further, recovering the neoantigens; as well as immunogenic compositions comprising these neoantigens. The disclosure further provides methods of inducing an immune response in a subject against a cancer such as glioblastoma; and methods of treating a cancer such as glioblastoma in a subject comprising administering to the subject a therapeutically effective amount of the neoantigens and compositions disclosed herein. | 2022-02-10 |
20220040280 | INHIBITORS AND USES THEREOF - Disclosed are lysine specific histone demethylase-1 (LSD1) inhibitors in methods and compositions for immune check-point inhibition. The invention also relates to proteinaceous molecules and their use in altering at least one of (i) formation, (ii) 5 N proliferation, (iii) maintenance, (iv) epithelial to mesenchymal cell transition (EMT), or (v) mesenchymal to epithelial cell transition (MET) of an LSD1 overexpressing cell. | 2022-02-10 |
20220040281 | RNA FOR MALARIA VACCINES - The present invention is directed to a coding RNA for a Malaria vaccine. The coding RNA comprises at least one heterologous untranslated region (UTR), preferably a 3′-UTR and/or a 5′-UTR, and a coding region encoding at least one antigenic peptide or protein derived from a Malaria parasite, in particular at least one antigenic protein derived from circumsporozoite protein (CSP) of a Malaria parasite (e.g. | 2022-02-10 |
20220040282 | LOW CONTAMINANT COMPOSITIONS - Disclosed are antimicrobial vaccines comprising oligosaccharide β-(1→6)-glucosamine groups. | 2022-02-10 |
20220040283 | Multivalent Pneumococcal Glycoconjugate Vaccines Containing Emerging Serotype 24F - The invention is directed to multivalent pneumococcal glycoconjugate compositions containing a newly emerging serotype of | 2022-02-10 |
20220040284 | VACCINES AND METHODS - Methods for identifying optimized antigenic pathogen polypeptides capable of inducing a broadly neutralizing immune response, and associated T-cell responses, to a pathogen are described, as well as nucleic acid sequences encoding such polypeptides. Methods for determining whether a broadly neutralizing immune response is induced in a subject following immunization with an optimized antigenic pathogen polypeptide, or a nucleic acid encoding the optimized pathogen polypeptide, are also described. Nucleic acid molecules, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, and their use as vaccines against pathogens, especially against emerging or re-emerging pathogens (particularly RNA viruses), are also described. | 2022-02-10 |
20220040285 | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response - The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. | 2022-02-10 |
20220040286 | COMPOSITIONS AND METHODS RELATED TO EBOLAVIRUS VACCINES - The present invention provides novel engineered | 2022-02-10 |
20220040287 | RECOMBINANT AVIAN HERPES VIRUSES CONTAINING MULTIPLE FOREIGN GENES - The present invention relates to recombinant avian herpes viruses containing multiple genes inserted into separate intergenic regions, their manufacture, compositions comprising the same, and the uses thereof. | 2022-02-10 |
20220040288 | HUMAN ROTAVIRUS G9P[6] STRAIN AND USE AS A VACCINE - Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy. | 2022-02-10 |
20220040289 | Rabies Composition Comprising Pika Adjuvant - The present disclosure provides a rabies composition comprising IPRV and PIKA adjuvant, and the pharmaceutical use thereof. The present disclosure also discloses a method for prophylaxis or therapeutic treatment of rabies virus infection, the method comprises a step of administering the rabies vaccine composition to a host. The rabies composition is more stable and safe, and is able to induce earlier and higher titers of neutralizing antibody. | 2022-02-10 |
20220040290 | COMPOSITIONS COMPRISING SUPRAMOLECULAR NANOFIBER HIV ENVELOPES AND METHODS FOR THEIR USE - The technology provides immunogenic compositions comprising HIV-1 envelopes in supramolecular nanofiber complexes, which may also comprise a T-cell helper epitopes, and methods of using these compositions for induction of immune responses. | 2022-02-10 |
20220040291 | HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION - Embodiments include a method of using inactivated human cold coronaviruses (HCoVs) particularly HCoV-299E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1, alone or as a booster, for the immunization against SARS-CoV-2 infections. Vaccine embodiments further comprise HCoV virus envelope subunits which may be in the form of virus-like spheroids (VLS). | 2022-02-10 |
20220040292 | Composition and Method of mRNA Vaccines Against Novel Coronavirus Infection - Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections. | 2022-02-10 |
20220040293 | HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION - Embodiments include a method of using inactivated human cold coronaviruses (HCoVs) particularly HCoV-299E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1, alone or as a booster, for the immunization against SARS-CoV-2 infections. Vaccine embodiments further comprise HCoV virus envelope subunits which may be in the form of virus-like spheroids (VLS). | 2022-02-10 |
20220040294 | ADMINISTRATION OF VACCINES TO SITES OF TEMPORALLY INDUCED CELL-MEDIATED HYPERSENSITIVITY REACTIONS, TO FACILITATE THE DEVELOPMENT OF PROTECTIVE SENSITIZATION AGAINST INFECTIOUS DISEASES AND CANCERS - Administration of an agent or substance to the site of a subject of a temporally interacting cell-mediated allergic reaction is used to enhance the resulting level of protective sensitization. | 2022-02-10 |
20220040295 | Treatment of Cancer With Naltrexone - The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumour/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone. | 2022-02-10 |
20220040296 | PAN-ANTIALLERGY VACCINE - The invention is directed to a protein construct comprising a scaffold protein into which an IgE epitope containing motif is inserted or substituted. The protein construct may be used as an antigen, immunogen or vaccine to induce immune responses against IgE in a vaccinated subject thereby reducing the severity of allergic phenomena associated with IgE. The invention is also directed to a method for designing such a protein construct and expressing it using recombinant DNA methods. | 2022-02-10 |
20220040297 | LIBRARY OF ANTIGEN-BINDING MOLECULES INCLUDING MODIFIED ANTIBODY VARIABLE REGION - The present inventors have successfully prepared a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, the antigen-binding molecules each comprising an antibody variable region that has binding activity against a first antigen and a second antigen different from the first antigen, but does not bind to the first antigen and the second antigen at the same time. Use of the library of the present invention allows the obtainment of a variable region having enhanced ability to bind to the first antigen and the production of a bispecific antibody against the first antigen and a cancer antigen. Moreover, the present inventors have also successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against three different antigens, but does not bind to these antigens at the same time. | 2022-02-10 |
20220040298 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY - The present invention is directed to the use of VISTA agonists alone or in association with other immune inhibitors, preferably another inhibitor of humoral immunity such as an iNOS/NO promoter or nitric oxide or a PD-1 or PD-L1 agonist or a CD40 antagonist for the treatment or prevention of conditions wherein the suppression of humoral immunity is therapeutically beneficial. The present invention is further directed to the use of VISTA antagonists alone or in association with other immune agonists, preferably another enhancer of humoral immunity such as iNOS/NO inhibitor or a PD-1 or PD-L1 antagonist or anti-CTLA-4 antibody or a CD40 agonist for the treatment or prevention of conditions wherein the enhancement of humoral immunity is therapeutically beneficial. Also, the invention relates to the use of VISTA antagonists alone or in association with another immune agonist, e.g., an iNOS/NO inhibitor or a CD40 agonist to promote the efficacy of therapeutic and prophylactic vaccines, e.g., antitumor, and antiviral vaccines. | 2022-02-10 |
20220040299 | METHODS OF TREATING CROHN'S DISEASE - The present invention generally relates to the treatment of Crohn's Disease with an anti-IL-23p19 antibody, particularly dosage regimens for the treatment of the disease. | 2022-02-10 |
20220040300 | METHOD OF FILLING A CONTAINER WITH NO HEADSPACE - The present invention is directed to methods for filling a container wherein the filled container has no headspace. The present invention is further directed to methods for stabilizing an aqueous drug substance solution by filling a container with the aqueous drug substance solution wherein the filled container has no headspace. The present invention is further directed to methods for detecting headspace in a container. | 2022-02-10 |
20220040301 | Anti-IL-6 Antibody Formulation - Provided herein are stable aqueous anti-IL-6 antibody formulations that have reduced aggregate formation and oxidation. The anti-IL-6 antibody formulations are suitable for treating IL-6 mediated diseases and disorders. | 2022-02-10 |
20220040302 | Method and apparatus for producing non-local physical, chemical and biological effects - A method and apparatus are disclosed which produce physical, chemical and/or biological non-local effect on a target substance through non-local processes mediated by quantum entanglement. In one broad embodiment, the apparatus includes a target substance, a first container holding said target substance; an originating substance, a second container holding said originating substance, said originating substance being quantum-entangled with said target substance; and a mean for manipulating said originating substance such that when said manipulation mean operates, said non-local effect is generated in said target substance through said non-local processes mediated by quantum entanglement. Also described are a number of implementations and methods of use of the apparatus, including a member of the manipulation mean being a Dewar filled with liquid nitrogen, a heater, a chemical substance, a laser or a magnetic coil connected to a driving device and the use being industrial, therapeutic, communicational or recreational. | 2022-02-10 |
20220040303 | BIOCOMPATIBLE NANOMAGNETIC DISCS AND METHODS OF USE THEREOF - Provided herein are compositions including biocompatible magnetizeable nanoparticles. The nanoparticles have a diameter (average diameter) from about 10 to about 300 nanometers and are biocompatible and magnetic. The nanoparticles may be a disc formed from iron oxide. The disc may be conjugated to a target-binding moiety capable of binding a target. The target may be cancer cells, pathogens, fat cells, or atherosclerotic plaques. | 2022-02-10 |
20220040304 | A COMPOSITION FOR CANCER CELL DEATH AND ITS USE - The present application relates to a cancer cell death composition and a cancer cell death method. The present application relates to an invention using a mechanism that provides reactive oxygen species to cell membranes of cancer cells, so as to break down the cell membranes of cancer cells, thereby enabling cancer cell death. | 2022-02-10 |
20220040305 | FORMULATIONS FOR HIGHLY PURIFIED VIRAL PARTICLES - Formulations for highly purified viral particles (e.g., adeno-associated virus (AAV) particles) are provided herein. The formulations include purified AAV particles that are substantially free of impurities (e.g., product-related impurities and process-related impurities), and one or more of a buffering agent, a cryoprotectant, a non-ionic surfactant, and optionally a pharmaceutically acceptable salt. In certain aspects, the formulation maintains or enhances stability and/or reduces or prevents aggregation of the purified AAV particles. | 2022-02-10 |
20220040306 | TOPICAL FORMULATIONS AND TREATMENTS - Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol. | 2022-02-10 |
20220040307 | PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE - This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount. | 2022-02-10 |
20220040308 | LIPID COMPOSITIONS - Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is | 2022-02-10 |
20220040309 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY - The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided. | 2022-02-10 |
20220040310 | Methods, agents and compositions as in situ vaccine for cancer cell and tumor treatment - This disclosure provides agents, compositions and methods for treating cancer by treating tumor in a subject. The composition comprises cancer cell inactivating agent and immune activity enhancing agent in a sustained release formulation, which can be used as intratumoral injection to convert the treated tumor into an in situ vaccine for cancer. Suitable immune activity enhancing agents include TLR agonist and STING agonist. | 2022-02-10 |
20220040311 | USE OF A MIXTURE OF LAUROYL MACROGOLGLYCERIDE AND POLYETHYLENE GLYCOL AS AN EXCIPIENT - The invention concerns the use, as a pharmaceutical or cosmetic excipient, of a composition which is solid at ambient temperature and in the form of individualized particles, said composition comprising:
| 2022-02-10 |
20220040312 | FORMULATIONS WITH REDUCED DEGRADATION OF POLYSORBATE - The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation. | 2022-02-10 |
20220040313 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION - A preserved liquid aqueous pharmaceutical composition includes one or more etherified cyclodextrin derivatives, at least one water-soluble preservative, and at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble. The liquid aqueous pharmaceutical composition provides an acceptable solubility of the pharmaceutically active compound, such as pimobendan, in aqueous solution whereby the water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivatives allowing the use in an oral administration form. | 2022-02-10 |